Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Berwick begins tenure at CMS

This article was originally published in The Gray Sheet

Executive Summary

Donald M. Berwick is sworn in as CMS administrator July 12 following a controversial recess appointment to the post (1"The Gray Sheet" July 12, 2010). Making his first official public appearance the next day at a press conference at HHS headquarters in Washington, D.C., Berwick touted the cost savings and health care quality improvements that could be gained from finalized rules on meaningful use of electronic health records. Republican lawmakers would like Berwick to make additional public appearances, specifically before congressional hearings that would explore his nomination and recess appointment. In a July 14 letter, Republican members of the Senate Finance Committee asked Committee Chair Max Baucus, D-Mont., to call a hearing "as soon as possible so that the President's recess appointment does not result in circumventing the open public review that should take place for a nomination of such importance." Republicans on the House Ways and Means Committee sent a similar letter, also dated July 14, to Committee Chair Sander M. Levin, D-Mich., stating "our nation's seniors deserve to know what is in store for their health care and how Dr. Berwick intends to manage an agency that controls almost $800 billion in taxpayer funds annually.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel